David Steele, MD
Gastroenterology · Birmingham, ALNPI 1215348396
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,764 of the $46,508 with a category attached, or 70.4%. Johnson & Johnson accounts for 83.4% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $23,769, more than ten times the $314 reported in 2019. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $90.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$39K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$733
- Bristol Myers Squibb$669
- QOL Medical, LLC$381
- plus $2K from 31 others
Across 39 payments — averaging $3497.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$72K
- Genentech, Inc.$62K
- AbbVie$3K
What the payments were for
- Speaking & faculty fees$32,76470%
- Travel & lodging$3,6218%
- Food & beverage$9,94521%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $38,770 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 121 | $2,097 |
| AbbVie | 90 | $1,367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $733 |
| Bristol Myers Squibb | 37 | $669 |
| QOL Medical, LLC | 16 | $381 |
| Pfizer | 15 | $357 |
| Lilly USA, LLC | 10 | $307 |
| Ardelyx, Inc. | 13 | $288 |
| Sanofi | 8 | $166 |
| Phathom Pharmaceuticals, Inc. | 12 | $146 |
| Gilead | 8 | $134 |
| Celltrion USA Inc. | 7 | $133 |
| AstraZeneca | 5 | $85 |
| Intercept Pharmaceuticals, Inc. | 6 | $85 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Ferring Pharmaceuticals Inc. | 4 | $60 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Redhill Biopharma Inc. | 3 | $53 |
| Amgen | 3 | $45 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| Evoke Pharma, Inc. | 3 | $42 |
| Braintree Laboratories, Inc. | 2 | $37 |
| Bayer | 2 | $31 |
| Merck | 2 | $30 |
| Conmed Corporation | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Mylan Institutional Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Organon | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Capsovision, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Ambu Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,508 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntyvioVedolizumab | 12 | $106,696 |
| LinzessLinaclotide | 62 | $51,730 |
| CreonLipase/Protease/Amylase | 11 | $26,645 |
| IbsrelaTenapanor Hcl | 11 | $19,148 |
| TrulancePlecanatide | 23 | $18,762 |
| VemlidyTenofovir Alafenamide | 12 | $17,395 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 110 | $14,821 |
| Mesalamine | 33 | $9,809 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 52 | $8,458 |
| Pantoprazole Sodium | 242 | $2,542 |
| Mesalamine ErMesalamine | 11 | $1,689 |
| Omeprazole | 74 | $1,077 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 56 | $998 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 43 | $828 |
| Esomeprazole Magnesium | 18 | $806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $733 | $106,69612 claims |
| AbbVieLinzess, Creon | $1,367 | $78,37573 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $2,097 | $33,583133 claims |
| Ardelyx, Inc.Ibsrela | $288 | $19,14811 claims |
| GileadVemlidy | $134 | $17,39512 claims |
| Braintree Laboratories, Inc.Sutab | $37 | $8,45852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Birmingham
- Robert ShafferBirmingham$1M
- Mukul MehraBirmingham$193K
- Meagan GrayBirmingham$113K
- Kirk RussBirmingham$38K
- Kenneth SigmanBirmingham$34K
- Shajan PeterBirmingham$31K
- Ali AhmedBirmingham$27K
- Swaroop VittaBirmingham$15K
- Rajat ParikhBirmingham$14K
- James CallawayBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.